Barinthus Biotherapeutics Revenue

Biotechnology Research • Didcot, England, United Kingdom • 51-100 Employees

Barinthus Biotherapeutics revenue & valuation

Annual revenue	$15,000,000
Revenue per employee	$238,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$48,000,000
Total funding	$168,000,000

Key Contacts at Barinthus Biotherapeutics

Alex Hammacher

Non Executive Director

Sushma Chauhan

Director Of Intellectual Property

Raleigh Edelstein Perez

Senior Director Of Biometrics

Meredith Lilley

Associate Director Of Clinical Operations

Dominick J. Laddy

Director, Program Management

Bryony Brien

Associate Director Of Fp&A And Finance Systems

Michael Dawson

It Director

Hugh Welles

Director Of Synthetic Immunotherapy Development

Tara Rist

Human Resources Director

Company overview

Headquarters	Units 6-10 Zeus Building, Rutherford Avenue, Harwell, Oxfordshire OX11 0DF, GB
Phone number	+441865818808
Website	barinthusbio.com
NAICS	541714
Keywords	Research, Oncology, Immunotherapy, Infectious Disease, Nanoparticles, Viral Vectors, Snap, HPV, Hepatitis B, Celiac, HBV, Prostate Cancer, Non-Small Cell Lung Cancer
Founded	2016
Employees	51-100
Socials

Barinthus Biotherapeutics Email Formats

Barinthus Biotherapeutics uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@barinthusbio.com), used 89.5% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@barinthusbio.com	89.5%
{first initial}.{last name}	j.doe@barinthusbio.com	10.5%

About Barinthus Biotherapeutics

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Helping people living with serious diseases and their families is the guiding principle at the heart of Barinthus Biotherapeutics. With a broad pipeline, built around four proprietary platform technologies: ChAdOx, MVA, SNAP-TI, and SNAP-CI; Barinthus Biotherapeutics is advancing a pipeline of five product candidates across a diverse range of therapeutic areas, including: VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; and VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer. Barinthus Biotherapeutics’ proven scientific expertise, diverse portfolio and focus on pipeline development uniquely positions the company to navigate towards delivering treatments for people with infectious diseases, autoimmunity and cancers that have a significant impact on their everyday lives.

Employees by Management Level

Total employees: 51-100

Seniority

Employees

Entry

Manager

Director

Employees by Department

Barinthus Biotherapeutics has 21 employees across 10 departments.

Departments

Number of employees

Funding Data

Explore Barinthus Biotherapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2021-04-17	5	$168,000,000

Funding Insights

$168,000,000

Total funding amount

$168,000,000

Most recent funding amount

Number of funding rounds

Barinthus Biotherapeutics Tech Stack

Discover the technologies and tools that power Barinthus Biotherapeutics's digital infrastructure, from frameworks to analytics platforms.

jQuery Mobile

Mobile frameworks

Drupal

CMS

Google Maps

Maps

jQuery Migrate

JavaScript libraries

Cloudflare

CDN

jQuery

JavaScript libraries

Apple iCloud Mail

Webmail

PHP

Programming languages

HSTS

Security

WordPress

Blogs

Divi

Page builders

Google Analytics

Analytics

Frequently asked questions

Barinthus Biotherapeutics is located in Didcot, England, GB.

You can reach Barinthus Biotherapeutics at +441865818808.

Barinthus Biotherapeutics generates an estimated annual revenue of $14,969,000. This revenue figure reflects the company's market position and business performance in its industry.

Barinthus Biotherapeutics has an estimated valuation of $48,000,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Barinthus Biotherapeutics was founded in 2016, making it 10 years old. The company has established itself as a significant player in its industry over this time.

Barinthus Biotherapeutics has approximately 51-100 employees. The company continues to grow its workforce to support its business operations and expansion.

Barinthus Biotherapeutics has raised a total of $168,000,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.